Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 9.44.
Forward PE Ratio (9.44) = Close Price ($28.07) / Consensus Forward EPS ($2.97)
FORWARD PE RATIO
9.44
SECTOR MEDIAN · HEALTHCARE
19.91
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
-52.60%
vs the sector median at left
Pfizer Inc.
Market Cap
$159.98B
Forward PE Ratio
9.44
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Pfizer Inc. (PFE) | $159.98B | 9.44 |
| Danaher Corporation (DHR)vs › | $153.85B | 25.74 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $139.10B | 29.24 |
| Gilead Sciences, Inc. (GILD)vs › | $181.42B | N/A |
| Bristol-Myers Squibb Company (BMY)vs › | $136.88B | 9.67 |
| Intuitive Surgical, Inc. (ISRG)vs › | $133.83B | 35.08 |
| Stryker Corporation (SYK)vs › | $126.30B | 21.93 |
| Medtronic plc (MDT)vs › | $119.49B | 16.92 |
| CVS Health Corp. (CVS)vs › | $118.69B | 11.66 |
| Abbott Laboratories (ABT)vs › | $201.83B | 21.14 |
Trailing P/E
37.1
reported TTM EPS
Forward P/E
9.4
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.97 implies +290.8% EPS growth vs the reported trailing $0.76.
At today's $28.07 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.97 | $2.87 – $3.09 | 14 | 9.4x |
| 2027-12-31 | $2.89 | $2.77 – $3.11 | 14 | 9.7x |
| 2028-12-31 | $2.49 | $1.60 – $3.02 | 8 | 11.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
